Novo Nordisk’s Wegovy weight loss drug wins UK approval for use as a heart treatment

CNBC July 23, 2024
Karen Gilchrist

Key Points

– The U.K.’s health regulator on Tuesday approved the use of Novo Nordisk’s Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes.

– It follows similar label expansion by the U.S. Food and Drug Administration in March.

LONDON — The U.K.’s health regulator on Tuesday approved the use of Novo Nordisk‘s Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes.

The new approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) makes the Danish pharmaceutical giant’s GLP-1 obesity drug the first in the country to be prescribed for prevention of cardiovascular events in people...

Today's Sponsors

Today's Sponsor